Analysis Tools|
Allele Symbol Allele Name Allele ID |
Tg(CDX2-cre/ERT2)752Erf transgene insertion 752, Eric Fearon MGI:5477802 |
||||||||||||||||||||
| Summary |
4 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• in an AOM/DSS model, tamoxifen-treated mice exhibit increased tumors number and burden compared to control mice
• however, Pol I inhibitor suppresses increased tumor growth
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 22.7% of mice injected with tamoxifen develop colonic dysplasia at 15 months post injection
|
|
• 9.1% of mice develop colon cancer at 15 months post injection with tamoxifen
|
|
• mice treated with colonic carcinogen azoxymethane (AOM) show higher tumor incidence (100%) compared to treated wild-type mice (67%) and have an increase in tumor number and burden compared with controls
|
|
• 9.1% of mice develop colon cancer at 15 months post injection with tamoxifen
|
|
• mice treated with colonic carcinogen azoxymethane (AOM) show higher tumor incidence (100%) compared to treated wild-type mice (67%) and have an increase in tumor number and burden compared with controls
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 19% of mice injected with tamoxifen develop colonic dysplasia at 15 months post injection
|
|
• mice treated with colonic carcinogen azoxymethane (AOM) show higher tumor incidence (100%) compared to treated wild-type mice (67%) and have an increase in tumor number and burden compared with controls
|
|
• mice treated with colonic carcinogen azoxymethane (AOM) show higher tumor incidence (100%) compared to treated wild-type mice (67%) and have an increase in tumor number and burden compared with controls
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• after tamoxifen (TAM) induction, most cells of the elongated colonic crypts are Ki67-positive, indicating colonic epithelial hyperplasia
|
|
• after TAM induction, colonic crypts exhibit significantly increased mRNA levels of markers for goblet cells (Muc2, Agr2) and secretory progenitors (Atoh1, Spdef and Neurog3), indicating increased mucin secretion
• however, mRNA levels of the stem cell marker Lgr5 are normal
|
|
• at 4 weeks after TAM induction, mice show significantly elongated crypts and compromised crypt integrity throughout the entire colon, with aberrant cell arrangements and irregular nuclei
• crypt elongation and loss of integrity is more evident in the proximal colon than in the mid to distal colon
• colonic crypts show a significant increase in Muc2 (mucin 2) expression
|
|
• after TAM induction, colonic crypts exhibit significantly increased mRNA levels of markers for goblet cells (Muc2, Agr2)
|
|
• after TAM induction, colonic crypts exhibit significantly increased mRNA levels of markers for goblet cells (Muc2, Agr2)
|
|
• after tamoxifen (TAM) induction, most cells of the elongated colonic crypts are Ki67-positive, indicating colonic epithelial hyperplasia
|
|
• after TAM induction, colonic crypts exhibit significantly increased mRNA levels of markers for goblet cells (Muc2, Agr2) and secretory progenitors (Atoh1, Spdef and Neurog3), indicating increased mucin secretion
• however, mRNA levels of the stem cell marker Lgr5 are normal
|
|
• at 4 weeks after TAM induction, mice show significantly elongated crypts and compromised crypt integrity throughout the entire colon, with aberrant cell arrangements and irregular nuclei
• crypt elongation and loss of integrity is more evident in the proximal colon than in the mid to distal colon
• colonic crypts show a significant increase in Muc2 (mucin 2) expression
|
|
• after TAM induction, colonic crypts exhibit significantly increased mRNA levels of markers for goblet cells (Muc2, Agr2)
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 11/12/2024 MGI 6.24 |
|
|
|
||
